Recall: D-0450-2022

Class II - Potentially Harmful

Class IIClassification

2021-12-29Initiated

TerminatedStatus

Aurobindo Pharma USA Inc.Firm

Product

Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05

Reason

Superpotent and Failed Tablet/Capsule Specifications

Distribution

Nationwide in the US

Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.